Use of 5α-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. [CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• SEER cancer statistics review, 1975-2016 [internet]. Bethesda, MD: National Cancer Institute. 2018. [cited November 2022]. Available from: https://seer.cancer.gov/csr/1975_2016/.
   Google Scholar
• Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239–248.
   PubMed Web of Science ®Google Scholar
• Lundberg E, Lagergren P, Mattsson F, et al. Life expectancy in survivors of esophageal cancer compared with the background population. Ann Surg Oncol. 2022;29(5):2805–2811.
   PubMed Web of Science ®Google Scholar
• Xie SH, Lagergren J. The male predominance in esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2016;14(3):338–347.e1.
   PubMed Web of Science ®Google Scholar
• Bohanes P, Yang D, Chhibar RS, et al. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 2012;30(18):2265–2272.
   PubMed Web of Science ®Google Scholar
• Lou L, Wang L, Zhang Y, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the global burden of disease study 2017. BMJ Open. 2020;10(1):e033323.
   PubMed Web of Science ®Google Scholar
• Li Y, Feng A, Zheng S, et al. Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis. Cancer Control. 2022;29:10732748221099227.
   Web of Science ®Google Scholar
• Xiang ZF, Xiong HC, Hu DF, et al. Age-related sex disparities in oesophagal cancer survival: a Population-Based study in the United States. Front Public Health. 2022;10:836914.
   PubMed Web of Science ®Google Scholar
• Morita M, Otsu H, Kawano H, et al. Gender differences in prognosis after esophagectomy for esophageal cancer. Surg Today. 2014;44(3):505–512.
   PubMed Web of Science ®Google Scholar
• Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440.
   PubMed Web of Science ®Google Scholar
• Fass R, Boeckxstaens GE, El-Serag H, et al. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021;7(1):55.
   PubMed Web of Science ®Google Scholar
• Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the international BEACON consortium. Int J Epidemiol. 2012;41(6):1706–1718.
   PubMed Web of Science ®Google Scholar
• Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015; 64(3):381–387.
   PubMed Web of Science ®Google Scholar
• Asplund J, Gottlieb-Vedi E, Leijonmarck W, et al. Prognosis after surgery for gastric adenocarcinoma in the swedish gastric cancer surgery study (SWEGASS). Acta Oncol. 2021;60(4):513–520.
   PubMed Web of Science ®Google Scholar
• Dong H, Xu J, Li W, et al. Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis. J Pathol. 2017;241(4):448–462.
   PubMed Web of Science ®Google Scholar
• McMenamin ÚC, Trainor J, Coleman HG, et al. Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. Oncotarget. 2018 19;9(82):35300–35312.
   PubMedGoogle Scholar
• Busby J, Karasneh R, Murchie P, et al. The role of 5α-reductase inhibitors in gastro-oesophageal cancer risk: a nested case-control study. Pharmacoepidemiol Drug Saf. 2020;29(1):48–56.
   PubMed Web of Science ®Google Scholar
• Rabbani S, Santoni G, Lagergren J, et al. Use of anti-androgenic 5α-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site. Br J Cancer. 2022;127(5):892–897.
   PubMed Web of Science ®Google Scholar
• Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58(1):16–23.
   PubMed Web of Science ®Google Scholar
• Petrick JL, Falk RT, Hyland PL, et al. Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR study. PLoS One. 2018;13(1):e0190325.
   PubMed Web of Science ®Google Scholar
• Xie SH, Ness-Jensen E, Rabbani S, et al. Circulating sex hormone levels and risk of esophageal adenocarcinoma in a prospective study in men. Am J Gastroenterol. 2020;115(2):216–223.
   PubMed Web of Science ®Google Scholar
• Goldenberg L, So A, Fleshner N, et al. The role of 5-alpha reductase inhibitors in prostate pathophysiology: is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009;3(3 Suppl 2):S109–S14.
   PubMed Web of Science ®Google Scholar
• Steers WD. 5alpha-reductase activity in the prostate. Urology. 2001;58(6 Suppl 1):17–24; discussion 24.
   PubMedGoogle Scholar
• Aggarwal S, Thareja S, Verma A, et al. An overview on 5α-reductase inhibitors. Steroids. 2010;75(2):109–153.
   PubMed Web of Science ®Google Scholar
• Kominea A, Konstantinopoulos PA, Kapranos N, et al. Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer. J Cancer Res Clin Oncol. 2004;130(5):253–258.
   PubMed Web of Science ®Google Scholar
• Gottlieb-Vedi E, Kauppila JH, Mattsson F, et al. Long-term survival in esophageal cancer after minimally invasive esophagectomy compared to open esophagectomy. Ann Surg. 2022;276(6):e744–e748.
   PubMed Web of Science ®Google Scholar
• Markar SR, Mackenzie H, Lagergren P, et al. Surgical proficiency gain and survival after esophagectomy for cancer. J Clin Oncol. 2016;34(13):1528–1536.
   PubMed Web of Science ®Google Scholar
• Ekström AM, Signorello LB, Hansson LE, et al. Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst. 1999;91(9):786–790.
   PubMedGoogle Scholar
• Lindblad M, Ye W, Lindgren A, et al. Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg. 2006;243(4):479–485.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Vall A, Mattsson F, et al. Tumour staging of oesophageal cancer in the Swedish cancer registry: a nationwide validation study. Acta Oncol. 2015;54(6):903–908.
   PubMed Web of Science ®Google Scholar
• Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish cancer register–a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.
   PubMed Web of Science ®Google Scholar
• Lagergren K, Derogar M. Validation of oesophageal cancer surgery data in the Swedish patient registry. Acta Oncol. 2012;51(1):65–68.
   PubMed Web of Science ®Google Scholar
• Brooke HL, Talbäck M, Hörnblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–773.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):450.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Armitage JN, van der Meulen JH. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson score. Br J Surg. 2010;97(5):772–781.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Svedberg P, Olén O, et al. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423–437.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater. J Urol. 2006;175(1):217–220.
   PubMed Web of Science ®Google Scholar
• Chiriacò G, Cauci S, Mazzon G, et al. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4(2):245–250.
   PubMed Web of Science ®Google Scholar
• Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354–373.
   PubMed Web of Science ®Google Scholar
• Student S, Hejmo T, Poterała-Hejmo A, et al. Anti-androgen hormonal therapy for cancer and other diseases. Eur J Pharmacol. 2020;866:172783.
   PubMed Web of Science ®Google Scholar
• Soleymani Fard S, Yazdanbod M, Sotoudeh M, et al. Prognostic and therapeutic significance of androgen receptor in patients with gastric cancer. Onco Targets Ther. 2020;13:9821–9837.
   PubMed Web of Science ®Google Scholar
• Ma WL, Hsu CL, Wu MH, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008;135(3):947–955. 955.e1-5.
   PubMed Web of Science ®Google Scholar
• Li Y, Izumi K, Miyamoto H. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol. 2012;42(7):569–577.
   PubMed Web of Science ®Google Scholar
• Konduri S, Schwarz MA, Cafasso D, et al. Androgen receptor blockade in experimental combination therapy of pancreatic cancer. J Surg Res. 2007;142(2):378–386.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558–568.
   PubMed Web of Science ®Google Scholar
• Feng H, Cheng AS, Tsang DP, et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest. 2011;121(8):3159–3175.
   PubMed Web of Science ®Google Scholar
• Zhang BG, Du T, Zang MD, et al. Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9. Oncotarget. 2014;5(21):10584–10595.
   PubMedGoogle Scholar
• Tang W, Liu R, Yan Y, et al. Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer. Oncotarget. 2017;8(25):40765–40777.
   PubMedGoogle Scholar
• Cooper SC, Trudgill NJ. Subjects with prostate cancer are less likely to develop esophageal cancer: analysis of SEER 9 registries database. Cancer Causes Control. 2012;23(6):819–825.
   PubMed Web of Science ®Google Scholar
• Shore R, Yu J, Ye W, et al. Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Sci Rep. 2021;11(1):13486.
   PubMed Web of Science ®Google Scholar
• Gan L, He J, Zhang X, et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer. 2012;12(1):566.
   PubMedGoogle Scholar
• Xie SH, Ness-Jensen E, Langseth H, et al. Prediagnostic circulating levels of sex hormones and survival in esophageal adenocarcinoma. Int J Cancer. 2021;148(4):905–913.
   PubMed Web of Science ®Google Scholar